Aflac (NYSE:AFL – Get Free Report) had its target price upped by JPMorgan Chase & Co. from $90.00 to $94.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the financial services provider’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 9.19% from the company’s previous close.
A number of other equities research analysts have also weighed in on AFL. TD Cowen initiated coverage on Aflac in a research report on Wednesday, October 9th. They set a “hold” rating and a $102.00 price objective on the stock. Truist Financial boosted their price objective on Aflac from $100.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Bank of America boosted their price objective on Aflac from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Barclays boosted their price objective on Aflac from $96.00 to $98.00 and gave the stock an “underweight” rating in a research report on Monday. Finally, Evercore ISI reduced their price objective on Aflac from $104.00 to $102.00 and set an “underperform” rating on the stock in a research report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $99.13.
Get Our Latest Research Report on AFL
Aflac Trading Up 0.7 %
Aflac (NYSE:AFL – Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The financial services provider reported $2.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.69 by $0.47. Aflac had a return on equity of 16.34% and a net margin of 22.02%. The company had revenue of $2.95 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the company posted $1.84 EPS. The company’s revenue for the quarter was down 40.4% compared to the same quarter last year. Equities analysts anticipate that Aflac will post 7.27 EPS for the current fiscal year.
Insider Activity
In other news, EVP Audrey B. Tillman sold 24,744 shares of the business’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $103.40, for a total value of $2,558,529.60. Following the transaction, the executive vice president now directly owns 222,618 shares of the company’s stock, valued at $23,018,701.20. The trade was a 10.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in Aflac by 75.2% during the 3rd quarter. Franklin Resources Inc. now owns 776,131 shares of the financial services provider’s stock worth $88,533,000 after buying an additional 333,083 shares during the period. Aptus Capital Advisors LLC raised its stake in Aflac by 79.7% during the 3rd quarter. Aptus Capital Advisors LLC now owns 27,354 shares of the financial services provider’s stock worth $3,058,000 after buying an additional 12,131 shares during the period. Transamerica Financial Advisors Inc. acquired a new position in Aflac during the 3rd quarter worth approximately $979,000. FMR LLC raised its stake in Aflac by 4.0% during the 3rd quarter. FMR LLC now owns 1,202,104 shares of the financial services provider’s stock worth $134,395,000 after buying an additional 45,745 shares during the period. Finally, Fulton Breakefield Broenniman LLC acquired a new position in Aflac during the 3rd quarter worth approximately $250,000. 67.44% of the stock is owned by institutional investors and hedge funds.
About Aflac
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Read More
- Five stocks we like better than Aflac
- Are Penny Stocks a Good Fit for Your Portfolio?
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- How to Plot Fibonacci Price Inflection Levels
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.